Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Loxo Oncology, Inc. (NASDAQ: LOXO).

Full DD Report for LOXO

You must become a subscriber to view this report.


Recent News from (NASDAQ: LOXO)

Midday Gainers / Losers (05/17/2018)
Gainers: CARV +78% . CPSH +40% . EGY +24% . EIGR +20% . LOXO +18% . BZUN +17% . BDSI +17% . RTTR +16% . ESND +15% . WWE +15% . More news on: Carver Bancorp, Inc., CPS Technologies Corp., VAALCO Energy, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:40
Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018)
Gainers : LOXO +19% . RTTR +18% . SPPI +17% . EIGR +16% . BDSI +15% . More news on: Loxo Oncology, Ritter Pharmaceuticals, Spectrum Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:21
Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data
Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (...and so on), is up strongly “following...
Source: SeekingAlpha
Date: May, 17 2018 12:00
Premarket Gainers as of 9:05 am (5/17/2018)
BLNK +16% . More news on: Blink Charging Co., Minerva Neurosciences, Loxo Oncology, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 09:19
Loxo's RET candidate LOXO-292 shows treatment effect in early-stage study, but still lags Blueprint's BLU-667
Loxo Oncology (NASDAQ: LOXO ) is up  18%  premarket on light volume on the heels of its announcement of interim data from a Phase 1 clinical trial assessing RET inhibitor LOXO-292 in RET-mutated cancers. Tumor shrinkage was observed in almost 70% of patients. More news on: Loxo...
Source: SeekingAlpha
Date: May, 17 2018 07:57
Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
Loxo Oncology +18% as cancer drug shows promise in early trial
Loxo Oncology (NASDAQ: LOXO ) +17.9% after-hours following preliminary results which showed that its new LOXO-292 experimental cancer drug led to tumor shrinkage in nearly 70% of patients regardless of where their cancer originated. More news on: Loxo Oncology, Blueprint Medicines, Hea...
Source: SeekingAlpha
Date: May, 16 2018 17:52
Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
– LOXO-292 Phase 1 Clinical Trial Abstract Selected for “Best of ASCO” – – Company to Host Conference Call and Webcast on Saturday, June 2 nd at 4:00 p.m. CT – STAMFORD, Conn., May 16, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq...
Source: GlobeNewswire
Date: May, 16 2018 17:00
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
The Ongoing Loxo Thesis, Part 2: The Journey Doesn't End With Larotrectinib
Note: Subscribers to the Total Pharma Tracker got an early look at this article, as well as access exclusive notes offering my opinions on the end game for these companies. You can try for free and join this conversation! In the first part of this article (click here to read if you h...
Source: SeekingAlpha
Date: May, 16 2018 00:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17160.50167.53171.989158.012,757,852
2018-02-26114.91112.64116.00112.27248,500
2018-02-23111.99113.91114.71109.24204,249
2018-02-22110.38111.16113.50109.54371,296
2018-02-21104.92107.68112.91104.92372,006

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-18105,882229,34946.1663Short
2018-05-17429,226945,66045.3890Short
2018-05-1666,267243,21027.2468Cover
2018-05-1575,864143,20152.9773Short
2018-05-1491,432201,81445.3051Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LOXO.


About Loxo Oncology, Inc. (NASDAQ: LOXO)

Logo for Loxo Oncology, Inc. (NASDAQ: LOXO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $4,188,265,425 - 05/11/2018
  • Issue and Outstanding: 30,034,173 - 02/23/2018

 


Recent Filings from (NASDAQ: LOXO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: LOXO)

Daily Technical Chart for (NASDAQ: LOXO)


Stay tuned for daily updates and more on (NASDAQ: LOXO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: LOXO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LOXO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of LOXO and does not buy, sell, or trade any shares of LOXO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/